Saturday, Sep 26, 2020 | Last Update : 06:13 PM IST

186th Day Of Lockdown

Maharashtra130045899280634761 Andhra Pradesh6614585881695606 Tamil Nadu5693705138369148 Karnataka5572124503028417 Uttar Pradesh3785333136865450 Delhi2644502284365147 West Bengal2410592110204665 Odisha201059165432820 Telangana1816271501601080 Bihar175898161510881 Assam167374136712625 Kerala160935111327636 Gujarat1303911105923394 Rajasthan1247301042881412 Haryana1205781012731273 Madhya Pradesh117588932382152 Punjab107096840253134 Chhatisgarh9856566860777 Jharkhand7770964515661 Jammu and Kashmir69832495571105 Uttarakhand4533233642555 Goa3107125071386 Puducherry2548919781494 Tripura2412717464262 Himachal Pradesh136799526152 Chandigarh112128677145 Manipur9791760263 Arunachal Pradesh8649623014 Nagaland5768469311 Meghalaya5158334343 Sikkim2707199431 Mizoram178612880
  Business   Companies  13 Aug 2020  J&J ties up with Biological E for manufacturing Covid vaccine in India

J&J ties up with Biological E for manufacturing Covid vaccine in India

THE ASIAN AGE.
Published : Aug 13, 2020, 9:02 pm IST
Updated : Aug 13, 2020, 9:02 pm IST

Hyderabad firm ties up to produce J&J's vaccine candidate in India

Mahima Datla, the managing director of Biological E
 Mahima Datla, the managing director of Biological E

Hyderabad: Biological E. Limited, India’s oldest biological products company, said on Thursday that it has tied up US-based Johnson & Johnson to manufacture the latter’s Covid-19 vaccine candidate in India.

“We are very pleased indeed to collaborate with an organisation like Johnson & Johnson. Given the magnitude of the Covid-19 pandemic, our ability to mount an effective response will be predicated on the ability to supply the vaccine globally and in significant quantities. This is best achieved through collaboration,” said Mahima Datla, the managing director of BE.

 

J&J is developing a vaccine candidate ‘Ad26.COV2.S’ for Coronavirus through its pharmaceutical arm Janssen Pharmaceutica NV. The vaccine candidate is currently in Phase 1/2a clinical trials.

The phase 1/2a study will involve more than 1,000 adults aged between 18 and 55. The study will also include an arm testing the vaccine in people 65 and older. Human trials in the Netherlands, Spain, Germany and Japan will follow.

Johnson & Johnson chief scientific officer Paul Stoffels had told a conference call last month that the company expects initial human results in September and phase 3 efficacy testing could start the same month itself. “The vaccine could be ready by early 2021,” he said.

 

The tie-up with Biological E. would help J&J to ramp its manufacturing capabilities in India.

“We look forward to deploying our manufacturing infrastructure to support Johnson & Johnson’s commitment to global access for its COVID-19 vaccine,” said Narender Dev Mantena, Director of BioE Holdings Inc., who heads BE’s novel vaccine initiative.

According to the World Health Organisation data, people around the world are working on 42 vaccine candidates for Coronavirus, including two from India, which are at different stages of development.

“Six vaccine candidates are in phase-3 trials, two candidates in phase 2 trials. Ten vaccine candidates, including two being developed in India, are at phase ½,” claims the WHO data as on August 10.

 

Tags: coronavirus (covid-19), covid vaccine